INNOCOLL HOLDINGS PLC
INNL evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- collaguard (Approved)
What it means
What to watch
Prepared research question
What matters most for INNL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
collaguard (Approved)
Next Catalyst
—
Tracking 2 pipeline candidates for INNOCOLL HOLDINGS PLC.
Run INNOCOLL HOLDINGS PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INNOCOLL HOLDINGS PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is INNOCOLL HOLDINGS PLC's lead drug candidate?
INNOCOLL HOLDINGS PLC's most advanced tracked candidate is collaguard (Approved) for prevention of post-operative adhesions.
What therapeutic areas does INNOCOLL HOLDINGS PLC focus on?
INNOCOLL HOLDINGS PLC develops therapies across Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.